https://www.selleckchem.com/products/U0126.html
Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population. Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.2 to 0.6 μg kg h ) in a non-operating theatre setting. We recorded local field potentials in 12 patients with Parkinson's dis
Gefällt mir
Kommentar
Teilen
